Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
UNITED THERAPEUTICS Corp reported three months ended December 31, 2023 results: revenue $614.7 million, net income $217.1 million, EPS $4.36 per diluted share.
- Period
- three months ended December 31, 2023
- Revenue
- $614.7 million
- Net income
- $217.1 million
- EPS
- $4.36 per diluted share
- Result
- reported results
Exact text from the filing
Key financial highlights include (in millions, except per share data): Three Months Ended December 31, Year Ended December 31, 2023 2022 2023 2022 Total revenues $ 614.7 $ 491.5 $ 2,327.5 $ 1,936.3 Net income $ 217.1 $ 132.1 $ 984.8 $ 727.3 Net income, per basic share $ 4.62 $ 2.88 $ 21.04 $ 15.98 Net income, per diluted share $ 4.36 $ 2.67 $ 19.81 $ 15.00
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
UNITED THERAPEUTICS Corp reported year ended December 31, 2023 results: revenue $2,327.5 million, net income $984.8 million, EPS $19.81 per diluted share.
- Period
- year ended December 31, 2023
- Revenue
- $2,327.5 million
- Net income
- $984.8 million
- EPS
- $19.81 per diluted share
- Result
- reported results
Exact text from the filing
(Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2023. Full year 2023 revenues rose to a record $2.33 billion, reflecting 20% growth over 2022. “Congratulations to the dedicated Unitherians who worked tirelessly to help us achieve our third straight quarter and second straight year of
View on SEC.gov